

November 13, 2002

MEMORANDUM

FROM William Tauber M.D., and Louis Marzella M.D., Ph.D.,
Clinical Reviewers, Infectious Diseases and Immunology
Branch

TO Karen Weiss M.D., Director, Division of Clinical Trial Design and Analysis, Office of
Therapeutics Research and Review, CBER

TOPIC Biologic License Application
BLA 125061-0
PEGASYS[®] (Peginterferon alfa-2a, Ro 25-8310) in Combination with COPEGUS[®]
(Ribavirin, Ro 20-9963) for the treatment of hepatitis C

ATTACHMENT Briefing Package
Antiviral Drugs Advisory Committee
November 14, 2002